Sharpepoint LLC Makes New $343,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Sharpepoint LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,405 shares of the medical device company's stock, valued at approximately $343,000.

Several other institutional investors and hedge funds have also modified their holdings of DXCM. Virtu Financial LLC bought a new position in DexCom during the 3rd quarter worth $1,020,000. Pine Valley Investments Ltd Liability Co increased its position in shares of DexCom by 59.2% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company's stock worth $381,000 after purchasing an additional 2,111 shares during the period. Sanctuary Advisors LLC increased its position in shares of DexCom by 32.2% in the third quarter. Sanctuary Advisors LLC now owns 14,835 shares of the medical device company's stock worth $1,080,000 after purchasing an additional 3,615 shares during the period. World Investment Advisors LLC acquired a new position in DexCom in the third quarter valued at about $2,351,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in DexCom during the third quarter worth about $381,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DXCM. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and upped their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Canaccord Genuity Group raised their target price on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

Insider Activity

In other news, EVP Michael Jon Brown sold 13,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares of the company's stock, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is currently owned by insiders.

DexCom Trading Up 5.9 %

NASDAQ:DXCM traded up $3.92 during trading hours on Thursday, hitting $70.78. 3,922,797 shares of the company were exchanged, compared to its average volume of 4,238,457. The stock has a market capitalization of $27.75 billion, a price-to-earnings ratio of 49.50, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24. The company has a fifty day simple moving average of $73.83 and a 200 day simple moving average of $76.60. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.